+1-646-568-9980, +44-203-287-6050
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
liquid biopsy market

Liquid Biopsy Market, [By Technology (Single Gene Analysis (PCR Microarrays), Multi-gene-parallel Analysis (NGS)); By Sample Type (Blood, Urine, Saliva, Other Body Fluid); By Biomarker (Exosomes, CTC, ctDNA); By Application (Molecular Health Monitoring, Therapy Selection for Other Meta Cancer, Therapy Selection for MBS); By Region]: Market Size & Forecast, 2018 – 2025

Published: Oct 2018
Pages: 135
Format: PDF
Report ID: PM1521
License and Pricing
Buy Now Inquire Before Buying

Report Summary

The worldwide Liquid Biopsy Market is estimated to grow at a CAGR of 14.9% between 2018 and 2025. Liquid Biopsy is a traditional technique used in diagnosis of cancer at an early stage. It is also termed as fluid biopsy or fluid phase biopsy.

This traditional technique is largely a non-invasive technique, which helps in proper tracking of tumors and mutations over a duration of time. These techniques provide doctors access to a range of information about the tumor’s future. Despite being a revolutionary technique, liquid biopsy has to face various challenges for its increasing adoption upon tissue biopsy. This minimally invasive technique is also used for detection of molecular biomarkers without costly and invasive surgeries. Blood is used as a most common medium for analysis as blood contains mainly two types of cancer-derived materials that are susceptible to the detailed molecular analysis. The commonly used types of liquid biopsy are CTC and Circulating tumor DNA (ctDNA) that are used to screen the presence of disease, ease for treating the patients according to the detected condition. Also, it provides an accurate snapshot of the genomic landscape of the tumor to influence the growth of this market.

Liquid Biopsy Market Share, By Biomarker Type, 2017 - 2025

Note: Inside circle depicts data for 2017 & outside circle depicts data for 2025

The liquid biopsy market is primarily driven by the increasing cases being detected for various types of cancer. Also, considering number of free trails and rising demand for liquid biopsy with minimal invasive surgeries is expected to boost the market growth during forecast period. Additionally, liquid biopsy is the fastest emerging substitute for tissue biopsy due to a smaller number of surgical invasions. Furthermore, rising number of mergers and acquisitions by the key players owing to the continuous research and development activities is also expected to have positive influence on the growth of liquid biopsy market in the near future.

Segment Analysis

The global liquid biopsy market is segmented on the basis of technology, sample type, biomarker, application, and geography. On the basis of technology type, the global liquid biopsy market is sub-segmented into single gene analysis (PCR Microarrays), and multi-gene-parallel analysis (NGS). NGS multiplex testing helps in diagnosis of multiple diseases at a single time, while PCR are based segmentation helps in analyzing the mutation in the genes. Hence, both technologies are observed to hold similar market shares.

Based on sample type, the global liquid biopsy market is sub-segmented into blood, urine, saliva, and other body fluid. Blood sample is the most common sample type that is used by doctors for proper analysis. Blood contains cell free DNA, circulating cell, and exosomes that can be detected easily, this helps in easy diagnosis of the cancer cell in the human body. Thus, there is an increase in the adoption of liquid biopsy with the help of blood sampling. Moreover, saliva and other body fluids sampling market to be the second largest market owing to the continuous research.

Based on the biomarker type, the global liquid biopsy market is further segmented into exosomes, CTC, and ctDNA. Circulating tumor cells (CTC) is expected to hold the largest market share owing the higher awareness of this technique, and its effective results for tracking cancer cell in the body. In addition, the early detection of the cells helps in appropriate diagnosis and clinical decisions related to cancer in initial stage itself.

The global liquid biopsy market covers application such as molecular health monitoring, therapy selection for other meta cancer, and therapy selection for MBS. Various therapy for treating meta cancer segment is expected to hold the major market share considering factors including the rising number of metastatic cancer incidences, and rising number of therapies for treating these cancers. Additionally, rising number of commercialized treatments for metastatic cancers to also drive growth of this market.

North America Liquid Biopsy Market, By Biomarker Type, 2017 - 2025
(USD Million)

Regional Analysis

The global Liquid Biopsy market geographically is sub segmented into; North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is observed to hold the dominating position in the global market during the forecast period. The factors that promote the growth of this market are increasing advanced accessibility for the diagnosis of various types of cancer, and increase number of patients suffering from cancer. While, Asia Pacific is supposed to grow at a faster rate during the forecast period. The growth of this market is majorly driven by the increasing investments by the key players in this region.

Competitive Landscape

The major players operating in this industry include Roche Diagnostics, Illumina, Inc., Bio-Rad Laboratories Inc., Myriad Genetics, Inc., Menarini Silicon Biosystems, Genomic Health, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Biocept, Inc., Trovagene, Inc., RainDance Technologies, Inc., Guardant Health, Inc., and MDx Health SA.


Key Take-Away